WO1996002553A3 - AMINO PURINE-β-D-RIBOFURANURONAMIDE DERIVATIVES - Google Patents
AMINO PURINE-β-D-RIBOFURANURONAMIDE DERIVATIVES Download PDFInfo
- Publication number
- WO1996002553A3 WO1996002553A3 PCT/EP1995/002837 EP9502837W WO9602553A3 WO 1996002553 A3 WO1996002553 A3 WO 1996002553A3 EP 9502837 W EP9502837 W EP 9502837W WO 9602553 A3 WO9602553 A3 WO 9602553A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- 6alkyl
- amino purine
- oxopyrrolidin
- piperidin
- solvates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU36982/95A AU3698295A (en) | 1994-07-14 | 1995-07-14 | Amino purine-beta -d-ribofuranuronamide derivatives |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9414193.4 | 1994-07-14 | ||
GB9414193A GB9414193D0 (en) | 1994-07-14 | 1994-07-14 | Compounds |
Publications (3)
Publication Number | Publication Date |
---|---|
WO1996002553A2 WO1996002553A2 (en) | 1996-02-01 |
WO1996002553A3 true WO1996002553A3 (en) | 1996-03-07 |
WO1996002553B1 WO1996002553B1 (en) | 1996-03-28 |
Family
ID=10758311
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1995/002837 WO1996002553A2 (en) | 1994-07-14 | 1995-07-14 | AMINO PURINE-β-D-RIBOFURANURONAMIDE DERIVATIVES |
Country Status (5)
Country | Link |
---|---|
AU (1) | AU3698295A (en) |
GB (1) | GB9414193D0 (en) |
IL (1) | IL114578A0 (en) |
WO (1) | WO1996002553A2 (en) |
ZA (1) | ZA955784B (en) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW528755B (en) * | 1996-12-24 | 2003-04-21 | Glaxo Group Ltd | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives |
YU44900A (en) | 1998-01-31 | 2003-01-31 | Glaxo Group Limited | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives |
PE20000270A1 (en) * | 1998-02-14 | 2000-05-20 | Glaxo Group Ltd | DERIVATIVES OF 2- (PURIN-9-IL) -TETRAHIDROFURAN-3,4-DIOL |
AU750462B2 (en) | 1998-06-23 | 2002-07-18 | Glaxo Group Limited | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives |
GB9813535D0 (en) * | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
GB9813540D0 (en) * | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
CA2336967C (en) | 1998-07-10 | 2010-06-29 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor antagonists |
US7427606B2 (en) * | 1999-02-01 | 2008-09-23 | University Of Virginia Patent Foundation | Method to reduce inflammatory response in transplanted tissue |
US6232297B1 (en) | 1999-02-01 | 2001-05-15 | University Of Virginia Patent Foundation | Methods and compositions for treating inflammatory response |
US7378400B2 (en) | 1999-02-01 | 2008-05-27 | University Of Virginia Patent Foundation | Method to reduce an inflammatory response from arthritis |
GB9924361D0 (en) | 1999-10-14 | 1999-12-15 | Pfizer Ltd | Purine derivatives |
AU3091301A (en) | 2000-01-14 | 2001-07-24 | Us Health | Methanocarba cycloalkyl nucleoside analogues |
US20010051612A1 (en) * | 2000-02-23 | 2001-12-13 | Gloria Cristalli | 2-Thioether A2A receptor agonists |
US6921753B2 (en) | 2000-06-27 | 2005-07-26 | Pfizer Inc | Purine derivatives |
SG176313A1 (en) | 2001-10-01 | 2011-12-29 | Univ Virginia Patent Found | 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof |
TW200519106A (en) | 2003-05-02 | 2005-06-16 | Novartis Ag | Organic compounds |
GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
AR049384A1 (en) | 2004-05-24 | 2006-07-26 | Glaxo Group Ltd | PURINA DERIVATIVES |
KR101167342B1 (en) | 2004-05-26 | 2012-07-19 | 이노텍 파마슈티컬스 코포레이션 | Purine derivatives as adenosine a1 receptor agonists and methods of use thereof |
WO2006023272A1 (en) | 2004-08-02 | 2006-03-02 | University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs having a2a agonist activity |
US7605143B2 (en) | 2004-08-02 | 2009-10-20 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs with modified 5′-ribose groups having A2A agonist activity |
WO2006028618A1 (en) | 2004-08-02 | 2006-03-16 | University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity |
AU2005286946B2 (en) | 2004-09-20 | 2012-03-15 | Inotek Pharmaceuticals Corporation | Purine derivatives and methods of use thereof |
GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
EP2532679B1 (en) | 2005-10-21 | 2017-04-12 | Novartis AG | Human antibodies against il13 and therapeutic uses |
AU2006320578B2 (en) | 2005-11-30 | 2013-01-31 | Inotek Pharmaceuticals Corporation | Purine derivatives and methods of use thereof |
GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
KR20080110925A (en) | 2006-04-21 | 2008-12-19 | 노파르티스 아게 | Purine derivatives for use as adenosin a2a receptor agonists |
WO2008037477A1 (en) | 2006-09-29 | 2008-04-03 | Novartis Ag | Pyrazolopyrimidines as p13k lipid kinase inhibitors |
JP2010508315A (en) | 2006-10-30 | 2010-03-18 | ノバルティス アーゲー | Heterocyclic compounds as anti-inflammatory agents |
WO2009006089A2 (en) * | 2007-06-29 | 2009-01-08 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | A2 adenosine receptor agonists |
ES2442930T3 (en) | 2008-01-11 | 2014-02-14 | Novartis Ag | Pyrimidines as kinase inhibitors |
DK2391366T3 (en) | 2009-01-29 | 2013-01-07 | Novartis Ag | Substituted benzimidazoles for the treatment of astrocytomas |
US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
AU2010283806A1 (en) | 2009-08-12 | 2012-03-01 | Novartis Ag | Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation |
JP5819831B2 (en) | 2009-08-17 | 2015-11-24 | インテリカイン, エルエルシー | Heterocyclic compounds and their use |
KR20120089463A (en) | 2009-08-20 | 2012-08-10 | 노파르티스 아게 | Heterocyclic oxime compounds |
US8518957B2 (en) | 2009-12-02 | 2013-08-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methanocarba adenosine derivatives, pharmaceutical compositions, and method of reducing intraocular pressure |
WO2011085361A1 (en) | 2010-01-11 | 2011-07-14 | Inotek Pharmaceuticals Corporation | Combination, kit and method of reducing intraocular pressure |
US8476247B2 (en) | 2010-03-26 | 2013-07-02 | Inotek Pharmaceuticals Corporation | Method of reducing intraocular pressure in humans |
US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
WO2012107500A1 (en) | 2011-02-10 | 2012-08-16 | Novartis Ag | [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase |
WO2012116237A2 (en) | 2011-02-23 | 2012-08-30 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
BR112013021638A2 (en) | 2011-02-25 | 2016-08-02 | Irm Llc | "trk inhibiting compounds, their use and compositions comprising them" |
EP2755976B1 (en) | 2011-09-15 | 2018-07-18 | Novartis AG | 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors |
US20130209543A1 (en) | 2011-11-23 | 2013-08-15 | Intellikine Llc | Enhanced treatment regimens using mtor inhibitors |
AU2013211957B2 (en) | 2012-01-26 | 2017-08-10 | Inotek Pharmaceuticals Corporation | Anhydrous polymorphs of (2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl) } methyl nitrate and processes of preparation thereof |
CA2868202C (en) | 2012-04-03 | 2021-08-10 | Novartis Ag | Combination products with tyrosine kinase inhibitors and their use |
CA2903114A1 (en) | 2013-03-15 | 2014-09-25 | Inotek Pharmaceuticals Corporation | Ophthalmic formulations |
CA2906542A1 (en) | 2013-03-15 | 2014-09-25 | Intellikine, Llc | Combination of kinase inhibitors and uses thereof |
TW201605450A (en) | 2013-12-03 | 2016-02-16 | 諾華公司 | Combination of Mdm2 inhibitor and BRAF inhibitor and their use |
WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
CA2954862A1 (en) | 2014-07-31 | 2016-02-04 | Novartis Ag | Combination therapy |
CN109879787A (en) * | 2019-01-10 | 2019-06-14 | 安徽昊帆生物有限公司 | Iodo acetylthiocholine, preparation method and its application |
TW202140550A (en) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | Methods of treating an inflammatory or obstructive airway disease using anti-tslp antibody |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0222330A2 (en) * | 1985-11-06 | 1987-05-20 | Warner-Lambert Company | N6-Substituted-5'-oxidized adenosine analogs |
WO1988003147A1 (en) * | 1986-10-31 | 1988-05-05 | Warner-Lambert Company | Selected n6-substituted adenosines having selective a2 binding activity |
EP0277917A2 (en) * | 1987-02-04 | 1988-08-10 | Ciba-Geigy Ag | Certain adenosine 5'-carboxamide derivatives |
-
1994
- 1994-07-14 GB GB9414193A patent/GB9414193D0/en active Pending
-
1995
- 1995-07-12 ZA ZA955784A patent/ZA955784B/en unknown
- 1995-07-13 IL IL11457895A patent/IL114578A0/en unknown
- 1995-07-14 WO PCT/EP1995/002837 patent/WO1996002553A2/en active Application Filing
- 1995-07-14 AU AU36982/95A patent/AU3698295A/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0222330A2 (en) * | 1985-11-06 | 1987-05-20 | Warner-Lambert Company | N6-Substituted-5'-oxidized adenosine analogs |
WO1988003147A1 (en) * | 1986-10-31 | 1988-05-05 | Warner-Lambert Company | Selected n6-substituted adenosines having selective a2 binding activity |
EP0277917A2 (en) * | 1987-02-04 | 1988-08-10 | Ciba-Geigy Ag | Certain adenosine 5'-carboxamide derivatives |
Non-Patent Citations (5)
Title |
---|
CRISTALLI G. ET AL: "2-Alkynyl Derivatives of Adenosine and Adenosine-5'-N-ethyluronamide as Selective Agonists of A2 Adenosine Receptors", JOURNAL OF MEDICINAL CHEMISTRY, vol. 35, WASHINGTON US, pages 2363 - 2368 * |
CRONSTEIN B.N.: "Adenosine, an endogenous anti-inflammatory agent", JOURNAL OF APPLIED PHYSIOLOGY, vol. 76, no. 1, pages 5 - 13 * |
HUTCHINSON A.J. ET AL: "2-(Arylalkylamino)adenosine-5'-uronamides: A New Class of Highly Selective Adenosine A2 Receptor Ligands", JOURNAL OF MEDICINAL CHEMISTRY, vol. 33, WASHINGTON US, pages 1919 - 1924 * |
TRIVEDI B.K. AND BRUNS R.F.: "C2,N6-Disubstituted Adenosines: Synthesis and Structure-Activity Relationships", JOURNAL OF MEDICINAL CHEMISTRY, vol. 32, WASHINGTON US, pages 1667 - 1673 * |
WOLLNER A ET AL: "Acting via A2 Receptors, Adenosine Inhibits the Upregulation of Mac-1 (CD11b/CD18) Expression on FMLP-stimulated Neutrophils", AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, vol. 9, pages 179 - 185 * |
Also Published As
Publication number | Publication date |
---|---|
IL114578A0 (en) | 1995-11-27 |
WO1996002553A2 (en) | 1996-02-01 |
ZA955784B (en) | 1996-08-15 |
AU3698295A (en) | 1996-02-16 |
GB9414193D0 (en) | 1994-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1996002553A3 (en) | AMINO PURINE-β-D-RIBOFURANURONAMIDE DERIVATIVES | |
CA2029420A1 (en) | Pharmaceutical compositions and methods for inhibition of maillard's reaction | |
WO1996002553B1 (en) | AMINO PURINE-β-D-RIBOFURANURONAMIDE DERIVATIVES | |
TW221053B (en) | ||
ES8608487A1 (en) | Benzimidazole derivatives and their thereapeutic and cosmetic use | |
MY114672A (en) | New erythromycin derivatives,processes for preparing them,the products thus prepared,pharmaceutical compositions containing them,and their use as medicaments | |
DE69021176D1 (en) | Polypeptide and process for its preparation. | |
HK1005544A1 (en) | Substituted 1,3-oxathiolanes with antiviral properties | |
EP0352581A3 (en) | Ethylene diaminmonoamide derivatives | |
DE68923151T2 (en) | Use of trifluoromethylphenyl tetrahydropyridines for the manufacture of medicaments for the treatment of anxio-depressive disorders. | |
EP0337628A3 (en) | 3-substituted-2-oxindole-1-carboxamides for suppressing t-cell function | |
EP0696585A4 (en) | ||
GB8720805D0 (en) | 2-alkoxy-n-(1-azabicyclo(2 2 2)oct-3-yl)benzamides & thiobenzamides | |
DE68925173D1 (en) | 4-methyl and 4-ethyl substituted pyrrolidin-2-ones | |
FR2449451B1 (en) | ||
EP0345598A3 (en) | Anthracycline derivatives with a cytostatic activity | |
EP0764443A4 (en) | Ameliorant or remedy for paraneoplastic syndrome | |
JO1889B1 (en) | New oxime derivativers of erythromycine a, their preparation, their applecation as medicaments and pharmaceutical comosetions contaning them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |